- Tags: AMD
Pipeline
SeaBeLife and Unither to formulate and develop retinal degenerative disorder formulation
Collaboration focuses on accelerating development of SBL03, formulated for topical delivery to target retinal cell necrosis in GA and dry AMD
Pipeline
Ocular Therapeutix plans for NDA submission of AXPAXLI for wet AMD
Company expects to submit package in Q1 2026, following the anticipated release of positive 1-year data from the phase 3 SOL-1 trial.
Research
Lifestyle behaviors play major role in preventing genetic risk for advanced AMD
Study assesses if lifestyle behaviors can offset the risk of AMD progression in those with high genetic susceptibility.
Pipeline
Coave Therapeutics debuts lead SCS gene therapy for retinal vascular diseases
In-office, suprachoroidal delivery of CoTx-101 offers potential for durable and long-lasting vision gains in treating wet AMD and DME.
Research
New 5-year Syfovre data indicates extended delay of GA progression
GALE extension study findings show delayed GA lesion growth by an estimated 1.5 years in patients receiving continuous treatment.
Business
LambdaVision raises $7M to advance space-based artificial retina
Biotech is using space and microgravity to produce its protein-based artificial retina, designed to restore vision in retinal degenerative diseased patients.
Pipeline
Outlook Therapeutics resubmits wet AMD BLA for bevacizumab
Company’s third submission of ONS-5010 (bevacizumab-vikg) reportedly addresses prior issues raised in the FDA’s company response letter.
Research
Advanced AMD linked to imbalanced gut microbiome
Though seemingly unrelated, gut flora may play a surprising role in the pathogenesis of age-related macular degeneration (AMD).
Products
Regeneron receives FDA CRL, delaying Eylea HD sBLA approval
Company plans to resubmit app for pre-filled syringe version in early 2026, noting two 2025 dates to watch for.
Business
Lilly to purchase Adverum Biotechnologies
With a Q4 closing date in mind, acquisition supports ongoing clinical trials and development activities for Ixo-vec, a one-time IVT gene therapy injection to treat wet AMD.
Research
Atopic dermatitis linked to increased risk for AMD
Study highlights importance of monitoring adult patients with atopic dermatitis for signs of AMD.
Pipeline
Complement Therapeutics' GA gene therapy IND receives FDA clearance
Clearance gives green light to begin Q1 2026 patient enrollment for the Opti-GAIN study evaluating CTx001 as a one-time, durable treatment.
Research
Lower AMD risk tied to long-term metformin use
Study joins growing body of research on the protective effect of metformin against AMD risk in diabetic patients.
Research
Real-world data support IZERVAY's long-term benefits
OLE trial of the GATHER2 study finds continued GA lesion growth for up to 3.5 years—with earlier intervention offering greater protection of the retinal tissue.
Products
FDA approves Celltrion's Eylea bisoimilar
EYDENZELT (aflibercept-bvoa) is indicated for patients with wet AMD, macular edema following RVO, DME, and DR.
Business
Ollin Biosciences debuts with next-gen ophthalmic pipeline
Biotech launches with $100 million financing and a lead program addressing wet AMD and DME via a higher potency VEGF/Ang2 bispecific antibody.
Legal
Regeneron settles with Sandoz over Eylea biosimilar patent infringement lawsuit
Agreement enables FDA-approved Enzeevu (aflibercept-abzv) to launch in Q4 2026, or potentially earlier.
Research
What factors impact visual acuity in intermediate AMD?
Study identifies three key features that impact visual acuity in patients with intermediate AMD.
Business
Alcon officially purchases LumiThera
Acquisition of the Valeda Light Delivery System includes plans to expand commercial market availability in 2026.
Pipeline